NewAmsterdam Pharma NAMS
$18.41 −$1.10 (-5.64%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $18.32 -0.49%
Open$19.21
Prev close$19.51
Day range$18.29 – $19.78
Volume1.75M
Market cap$2.21B
P/E (TTM)–
Dividend yield–
NAMS Stock News
Headlines matching NewAmsterdam Pharma or the NAMS ticker, most recent first.
- Stifel Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $50
- Truist Financial Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating
- H.C. Wainwright Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $52
- BMO Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $58
- Truist Financial Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Announces Target Price $57
- William Blair Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating
- Needham Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $48
- A Quick Look at Today's Ratings for NewAmsterdam Pharma(NAMS.US), With a Forecast Between $50 to $52
- A Quick Look at Today's Ratings for NewAmsterdam Pharma(NAMS.US), With a Forecast Between $50 to $58
- Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $60
- BMO Capital Initiates NewAmsterdam Pharma(NAMS.US) With Buy Rating, Announces Target Price $58
- RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Raises Target Price to $51 Positive
- Guggenheim Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $45
- A Quick Look at Today's Ratings for NewAmsterdam Pharma(NAMS.US), With a Forecast Between $45 to $48
- H.C. Wainwright Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)
No comments yet — be the first to weigh in on NAMS.
Sign in to join the discussion.